Changed Drugs for High BP

Question:

Respected Sir,

Many regards from India. Sir, as you have responded my queries in the past, I am encouraged to ask you this query.

Currently I am on Tenormin 100 Losartan 100 and Indapamide 1.5 Amlodepine 10 mg. Recently in a reputed hospital, I had a healyh check up where all the parameters of the blood were normal except that my 2D echo stated Severe LVH with Dystolic dyfunction EF 65%. Cardiologist made changes ; He suggested Tenormin 100 to Bispoprolol 5 mg Telmisartan 80 in place of Losartan 100 Other drugs to continue. Further, he asked me to take Rosuvastatin 10 mg as according to him all hypertensive patients need to take statin. I have a BP Male 51 years My lipid levels are normal. I have a impaired glucose tolerance for which he suggested Metformin 500mg. I am now at a different place I do not know whether the change is a good one. I seek your guidance as to whether the changed drug regimen is OK. Mainly I have HBP ( Essential HBP)Tachycardia and IGT) I shall be highly obliged to receive your detailed

Changed Drugs for High BP

Question:

Respected Sir,

Many regards from India. Sir, as you have responded my queries in the past, I am encouraged to ask you this query.

Currently I am on Tenormin 100 Losartan 100 and Indapamide 1.5 Amlodepine 10 mg. Recently in a reputed hospital, I had a healyh check up where all the parameters of the blood were normal except that my 2D echo stated Severe LVH with Dystolic dyfunction EF 65%. Cardiologist made changes ; He suggested Tenormin 100 to Bispoprolol 5 mg Telmisartan 80 in place of Losartan 100 Other drugs to continue. Further, he asked me to take Rosuvastatin 10 mg as according to him all hypertensive patients need to take statin. I have a BP Male 51 years My lipid levels are normal. I have a impaired glucose tolerance for which he suggested Metformin 500mg. I am now at a different place I do not know whether the change is a good one. I seek your guidance as to whether the changed drug regimen is OK. Mainly I have HBP ( Essential HBP)Tachycardia and IGT) I shall be highly obliged to receive your detailed

Adderall and High Blood Pressure

Question:

I have tried several anxiety meds over the last year: Effexor shot my blood pressure up, Zoloft made me gain a ton of weight in a short amount of time, wellbutrin did not work for me either. I recently started taking Adderall after discussing my symptoms with my dr. It has been by FAR the most helpful, HOWEVER, around 6:00pm every night, my blood pressure shoots up to 148/106 or some other horrible number. Why does it do that when I am coming down? I only take it in morning because a lunchtime dose would affect my sleeping. I am currently on 20 mgs in AM, and that lasts majority of day for me. It is just in the evenings that I have a problem when blood pressure goes up: headaches, nausea….I am wondering if I need to stop taking it or try something else.

High blood pressure

Question:

I got high blood pressure from taking Prednisone. Now I am down to 5mg a day. The doctor already lowered one of my drugs because it was causing my blood pressure to go to low and I had very bad dizzy/fainting spells. Now that my blood pressure is normal or below normal I would like to come off both of my drugs that I use for my blood pressure. Since I reduced the Prednisone can this cause me to cure my high blood pressure?

A Novel Method Of Isolating High Quality RNA From Kupffer Cells

Kupffer cells, resident tissue macrophages that line the liver sinusoids, play a key role in modulating inflammation in a number of experimental models of liver injury. Since Kupffer cells represent only a small portion of the entire liver cell population, greatly outnumbered by the parenchymal cells, Kupffer cell isolation faces major technical obstacles. Laser capture microdissection (LCM) offers a method of isolating a single cell type from specific regions of tissue sections.

Palonosetron Warrants Adequate Caloric Intake In Oncology Patients Receiving High Emetogenic Chemotherapy

A new, innovative study shows that a single dose of palonosetron, the second generation 5-HT3 antagonist, plus dexamethasone not only prevents chemotherapy-induced nausea and vomiting (CINV), but also allows adequate caloric intake in oncology patients. Data presented at the ESMO Symposium on Cancer and Nutrition in Zurich, Switzerland

New data presented today at the ESMO (European Society of Medical Oncology) Symposium on Cancer and Nutrition in Zurich shows that palonosetron, a second generation 5-HT3 receptor antagonist, warrants adequate caloric intake in oncology patients receiving high emetogenic chemotherapy (HEC). The result comes from an innovative study conducted in the Oncology Institute of Ospedale V. Fazzi of Lecce, Italy, by the research team of Dr. Vito Lorusso. The findings confirmed the efficacy of a single dose of palonosetron and dexamethasone to control chemotherapy-induced nausea and vomiting (CINV) episodes in patients treated with HEC (cisplatin and/or epirubicin and/or iphosphamide) for soft tissue sarcoma: 76% of the patients achieved complete response (no vomiting, no use of rescue medication), 74% complete control (complete response and no more than mild nausea), in the 7-day period following chemotherapy, after palonosetron treatment.

AP/Washington Times Examines Factors Behind High Maternal Mortality In Haiti

The AP/Washington Times on Tuesday examined the high maternal mortality rate in Haiti and the efforts of international not-for-profits, including the Clinton Global Initiative and Doctors Without Borders, to address the issue. According to a 2008 UNICEF report, 670 women died from pregnancy-related factors for every 100,000 live births in Haiti in 2006. By contrast, in the U.S. that year, 11 women died for every 100,000 live births. Haiti’s maternal mortality rate is more than five times the Latin American and Caribbean average, and it is higher than any South Asian or Middle Eastern country except Afghanistan and Nepal. Wendy Lai of Doctors Without Borders Holland called the situation “embarrassing to the Western world.” She added, “[T]hese are preventable deaths.”

High HPV Vaccination Coverage Already Achieved In England

More than 70 per cent of 12-13 year old girls have already had their first HPV (human papillomavirus) jab since the vaccination campaign started in September, Public Health Minister Dawn Primarolo announced today. This figure will rise as more results come in.

The success of the campaign has prompted the Department of Health to announce that the catch up campaign to vaccinate girls aged 13-17 years will be brought forward to next year.

Maryland Preparedness Effort Gets High Mark From CDC

Governor Martin O’Malley today announced that Maryland’s Strategic National Stockpile (SNS) Plan received a high mark from the national Centers for Disease Control and Prevention (CDC). The plan, developed by staff within the Department of Health and Mental Hygiene (DHMH), received a score of 93 out of a possible 100, up considerably from its previous score of 67 received in 2007.

“This score represents a marked improvement and shows Maryland’s commitment to make government work,” Governor O’Malley said. “The dedication and commitment put forth by Secretary John Colmers and Sherry Adams, director of the DHMH Office of Preparedness and Response, have put Maryland in a much better position to respond to emergencies.”

Study Of Revlimid And Vidaza In Higher-Risk MDS Is Well-Tolerated And Has High Activity

Celgene International Sarl (NASDAQ: CELG) reported that results of a Phase I study combining REVLIMID and VIDAZA in patients with higher-risk myelodysplastic syndromes (MDS) found that the combination of these two therapies is well tolerated and has high activity. The data were reported during the 50th Annual Meeting of the American Society of Hematology.

“Lenalidomide and azacitidine have demonstrated significant activity as single agents in lower- and higher-risk MDS patients respectively,” said Mikkael A. Sekeres, M.D. Cleveland Clinic Taussig Cancer Institute, the lead investigator of the study and consultant to Celgene. “By combining the immunomodulatory, anti-angiogenic and cytotoxic properties of lenalidomide and the DNA demethylating and cytotoxic activities of azacitidine we expect greater efficacy in patients with MDS and AML. These results report a well-tolerated and effective regimen.”